Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
BioSpace
While an acquisition is a good exit for Soleno Therapeutics, the company's acceptance of Neurocrine Biosciences' $53-per-share offer came as a surprise to Stifel analysts given the potential growth of
pharminent
April 6, 2026 (Last updated: April 6, 2026)
BioSpace
While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of
